{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:23:36Z","timestamp":1793993016815,"version":"4.8.0"},"reference-count":103,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Lower anogenital tract malignancies comprise anatomically adjacent but biologically heterogeneous epithelial cancers of the cervix, vulva, vagina, anal canal and penis. This narrative and conceptual Review used a transparent literature search to examine how human papillomavirus (HPV) etiology intersects with tumor lineage, somatic alterations, antigen-presentation competence, immune-cell state and spatial organization. Evidence quality is heterogeneous: cervical cancer is supported by the largest genomic, single-cell, spatial and randomized-trial literature, whereas vaginal, vulvar and penile cancers remain constrained by small retrospective cohorts and cross-site extrapolation. HPV-associated tumors retain non-self E6\/E7 antigens, but viral transcription does not ensure peptide presentation, dendritic-cell priming or epithelial access by functional T cells. HPV-independent tumors lack constitutive viral antigens yet may generate mutation- or differentiation-derived immunity and checkpoint-restrained myeloid\u2013lymphoid niches. We therefore distinguish etiological status from functional immune phenotype and critically appraise three spatial architectures\u2014an inflamed\/epithelial-penetrating pattern, a stromally excluded pattern, and an immune-desert pattern\u2014together with an immunosuppressive functional overlay that may occur in any architecture. Clinical evidence is graded separately from mechanistic inference: immune checkpoint blockade has established roles in defined cervical and anal cancer settings, whereas therapeutic vaccines, tumor-infiltrating lymphocytes, T-cell receptor-engineered therapies, myeloid or stromal sensitization and artificial-intelligence-guided selection remain investigational or context dependent. A three-tier biomarker framework is proposed, separating routine clinical assays from extended translational profiling and exploratory single-cell, spatial and artificial-intelligence methods. This framework is hypothesis-generating, not a validated treatment-selection algorithm; assay combinations, thresholds and incremental clinical utility require prospective, multicenter and site-stratified validation.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1937031","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:09:45Z","timestamp":1790082585000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Divergent immune ecosystems in HPV-associated and HPV-independent lower anogenital tract malignancies"],"prefix":"10.3389","volume":"17","author":[{"given":"Hongmei","family":"Wang","sequence":"first","affiliation":[{"name":"School of Basic Medicine, Shaanxi University of Chinese Medicine","place":["Xianyang, Shaanxi, China"]},{"name":"Department of Gynecology, Affiliated Hospital of Shaanxi University of Chinese Medicine","place":["Xianyang, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifeng","family":"Sun","sequence":"additional","affiliation":[{"name":"Hubei Clinical Research Center for Reproductive Medicine","place":["Shiyan, Hubei, China"]},{"name":"Hubei Key Laboratory of Wudang Local Chinese Medicine Research, Shiyan Key Laboratory of Reproduction and Genetics (Renmin Hospital), Hubei University of Medicine","place":["Shiyan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanlin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Innovation Team for Prevention and Treatment of Neurodegenerative Diseases with Traditional Chinese Medicine, Shaanxi University of Chinese Medicine, Key Laboratory for Prevention and Treatment of Cerebrospinal Diseases, Administration of Traditional Chinese Medicine of Shaanxi Province","place":["Xianyang, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongli","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Affiliated Hospital of Shaanxi University of Chinese Medicine","place":["Xianyang, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(19)30488-7","article-title":"Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis","volume":"8","author":"de Martel","year":"2020","journal-title":"Lancet Glob Health"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pky045","article-title":"Burden of human papillomavirus-related cancers attributable to HPVs 6\/11\/16\/18\/31\/33\/45\/52 and 58","volume":"2","author":"de Sanjose","year":"2019","journal-title":"JNCI Cancer Spectr"},{"key":"B3","volume-title":"Female Genital Tumours","year":"2020"},{"key":"B4","volume-title":"Urinary and Male Genital Tumours","year":"2022"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12472","article-title":"HPV-related cancers after solid organ transplantation in the United States","volume":"13","author":"Madeleine","year":"2013","journal-title":"Am J Transplant"},{"key":"B6","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0140-6736(07)61050-2","article-title":"Incidence of cancers in people with HIV\/AIDS compared with immunosuppressed transplant recipients: a meta-analysis","volume":"370","author":"Grulich","year":"2007","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/his.14925","article-title":"Human papillomavirus and p53 status define three types of vulvar squamous cell carcinomas with distinct clinical, pathological, and prognostic features","volume":"83","author":"Carreras-Dieguez","year":"2023","journal-title":"Histopathology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/his.13995","article-title":"Cervical adenocarcinoma: integration of HPV status, pattern of invasion, morphology and molecular markers into classification","volume":"76","author":"Park","year":"2020","journal-title":"Histopathology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000986","article-title":"International Endocervical Adenocarcinoma Criteria and Classification (IECC): a new pathogenetic classification for invasive adenocarcinomas of the endocervix","volume":"42","author":"Stolnicu","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2886","article-title":"Human papillomavirus oncoproteins: pathways to transformation","volume":"10","author":"Moody","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31027","article-title":"Immune evasion mechanisms of human papillomavirus: an update","volume":"142","author":"Steinbach","year":"2018","journal-title":"Int J Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00682","article-title":"Papillomavirus immune evasion strategies target the infected cell and the local immune system","volume":"9","author":"Zhou","year":"2019","journal-title":"Front Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29685","article-title":"High-risk HPV oncoproteins E6 and E7 and their interplay with the innate immune response: uncovering mechanisms of immune evasion and therapeutic prospects","volume":"96","author":"Lo Cigno","year":"2024","journal-title":"J Med Virol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000800","article-title":"HR-HPV E6\/E7 mRNA in situ hybridization: validation against PCR, DNA in situ hybridization, and p16 immunohistochemistry in 102 samples","volume":"41","author":"Mills","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/nature21386","article-title":"Integrated genomic and molecular characterization of cervical cancer","volume":"543","year":"2017","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006211","article-title":"The role of integration in oncogenic progression of HPV-associated cancers","volume":"13","author":"McBride","year":"2017","journal-title":"PloS Pathog"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910460614","article-title":"Loss of MHC class-I expression in cervical carcinomas","volume":"46","author":"Connor","year":"1990","journal-title":"Int J Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910570507","article-title":"Biological-clinical significance of selective loss of HLA-class-I allelic product expression in squamous-cell carcinoma of the uterine cervix","volume":"57","author":"Honma","year":"1994","journal-title":"Int J Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1100354108","article-title":"HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8-positive T lymphocytes","volume":"108","author":"Gooden","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1008334","article-title":"Cervical (pre)neoplastic microenvironment promotes the emergence of tolerogenic dendritic cells via RANKL secretion","volume":"4","author":"Demoulin","year":"2015","journal-title":"Oncoimmunology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-0385","article-title":"Cervical cancer evades the host immune system through the inhibition of type I interferon and CXCL9 by LIF","volume":"30","author":"Bonfill-Teixidor","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202203040","article-title":"Single-nucleus RNA sequencing and spatial transcriptomics reveal the immunological microenvironment of cervical squamous cell carcinoma","volume":"9","author":"Ou","year":"2022","journal-title":"Adv Sci (Weinh)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41698-025-00948-z","article-title":"Deciphering the cellular and molecular landscape of cervical cancer progression through single-cell and spatial transcriptomics","volume":"9","author":"Xia","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1612623","article-title":"Integrated multi-omics analysis of single-cell and spatial transcriptomics reveals distinct HPV-associated immune microenvironment features and prognostic signatures in cervical cancer","volume":"16","author":"Su","year":"2025","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.897366","article-title":"Dissecting the single-cell transcriptome network of immune environment underlying cervical premalignant lesion, cervical cancer and metastatic lymph nodes","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28857","article-title":"Diverse intratumoral heterogeneity and immune microenvironment of two HPV-related cervical cancer types revealed by single-cell RNA sequencing","volume":"95","author":"Li","year":"2023","journal-title":"J Med Virol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1522655","article-title":"Single-cell RNA sequencing and immune microenvironment analysis reveal PLOD2-driven malignant transformation in cervical cancer","volume":"15","author":"Lin","year":"2025","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41392-022-01264-9","article-title":"Single-cell RNA-sequencing reveals radiochemotherapy-induced innate immune activation and MHC-II upregulation in cervical cancer","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B29","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/s41419-024-07128-0","article-title":"YTHDF1 boosts the lactate accumulation to potentiate cervical cancer cells immune escape","volume":"15","author":"Xiong","year":"2024","journal-title":"Cell Death Dis"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1186\/s12967-024-06011-y","article-title":"Spatial transcriptomics reveals unique metabolic profile and key oncogenic regulators of cervical squamous cell carcinoma","volume":"22","author":"Zhou","year":"2024","journal-title":"J Transl Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2016.08.011","article-title":"LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells","volume":"24","author":"Brand","year":"2016","journal-title":"Cell Metab"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic competition in the tumor microenvironment is a driver of cancer progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0382-2","article-title":"The adenosine pathway in immuno-oncology","volume":"17","author":"Allard","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-24-0979","article-title":"Tertiary lymphoid structures are associated with enhanced macrophage activation and immune checkpoint expression and predict outcome in cervical cancer","volume":"13","author":"Gorvel","year":"2025","journal-title":"Cancer Immunol Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1914-8","article-title":"Tertiary lymphoid structures improve immunotherapy and survival in melanoma","volume":"577","author":"Cabrita","year":"2020","journal-title":"Nature"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1906-8","article-title":"B cells are associated with survival and immunotherapy response in sarcoma","volume":"577","author":"Petitprez","year":"2020","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-020-00726-1","article-title":"Massively parallel sequencing analysis of 68 gastric-type cervical adenocarcinomas reveals mutations in cell cycle-related genes and potentially targetable mutations","volume":"34","author":"Selenica","year":"2021","journal-title":"Mod Pathol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/cjp2.345","article-title":"Expression of B7-H3 and TIM-3 in gastric-type endocervical adenocarcinoma: prevalence, association with PD-L1 expression, and prognostic significance","volume":"10","author":"Sun","year":"2024","journal-title":"J Pathol Clin Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000532","article-title":"Gastric-type endocervical adenocarcinoma: an aggressive tumor with unusual metastatic patterns and poor prognosis","volume":"39","author":"Karamurzin","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/ijc.28963","article-title":"Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide","volume":"136","author":"Alemany","year":"2015","journal-title":"Int J Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.20","article-title":"HPV-negative squamous cell carcinoma of the anal canal is unresponsive to standard treatment and frequently carries disruptive mutations in TP53","volume":"112","author":"Meulendijks","year":"2015","journal-title":"Br J Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw152","article-title":"Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes","volume":"27","author":"Chung","year":"2016","journal-title":"Ann Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-020-00729-y","article-title":"Molecular and immunophenotypic characterization of anal squamous cell carcinoma reveals distinct clinicopathologic groups associated with HPV and TP53 mutation status","volume":"34","author":"Zhu","year":"2021","journal-title":"Mod Pathol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41698-024-00585-y","article-title":"Inflammatory pathways confer resistance to chemoradiotherapy in anal squamous cell carcinoma","volume":"8","author":"Martin","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.09.024","article-title":"Vulvar cancer subclassification by HPV and p53 status results in three clinically distinct subtypes","volume":"159","author":"Kortekaas","year":"2020","journal-title":"Gynecol Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16244216","article-title":"Molecular subtypes of vulvar squamous cell carcinoma: the significance of HPV-independent\/p53 wild type","volume":"16","author":"Horn","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B47","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ygyno.2025.01.002","article-title":"Spatial transcriptomic analysis reveals significant differences in tumor microenvironment in HPV-dependent and HPV-independent vulvar squamous cell carcinoma","volume":"193","author":"Mirza","year":"2025","journal-title":"Gynecol Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgc.2024.100051","article-title":"Molecular and microenvironmental landscapes of human papillomavirus-independent invasive squamous cell carcinoma of the vulva","volume":"35","author":"Moufarrij","year":"2025","journal-title":"Int J Gynecol Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003671","article-title":"Primary vulvar squamous cell carcinomas with high T-cell infiltration and active immune signaling are potential candidates for neoadjuvant PD-1\/PD-L1 immunotherapy","volume":"9","author":"Kortekaas","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.07.018","article-title":"Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples","volume":"50","author":"Alemany","year":"2014","journal-title":"Eur J Cancer"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.7078","article-title":"The prognostic role of HPV or p16INK4a status in penile squamous cell carcinoma: a meta-analysis","volume":"23","author":"Mustasam","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1463445","article-title":"Human papillomavirus infection affects the immune microenvironment and antigen presentation in penile cancer","volume":"14","author":"Guimaraes","year":"2024","journal-title":"Front Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202500216","article-title":"Single-cell and spatial transcriptomic profiling of penile squamous cell carcinoma reveals dynamics of tumor differentiation and immune microenvironment","volume":"12","author":"Song","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01253","article-title":"The prognostic value of immune factors in the tumor microenvironment of penile squamous cell carcinoma","volume":"9","author":"Ottenhof","year":"2018","journal-title":"Front Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-024-04013-1","article-title":"Tumor-infiltrating plasma cells are a prognostic factor in penile squamous cell carcinoma","volume":"487","author":"Stenzel","year":"2025","journal-title":"Virchows Arch"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35177","article-title":"Human papillomavirus infection affects treatment outcomes and the immune microenvironment in patients with advanced penile squamous cell carcinoma receiving PD-1 inhibitor-based combination therapy","volume":"130","author":"Wei","year":"2024","journal-title":"Cancer"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2014.11.057","article-title":"Classic and nonclassic HLA class I expression in penile cancer and relation to HPV status and clinical outcome","volume":"193","author":"Djajadiningrat","year":"2015","journal-title":"J Urol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","article-title":"Defining T cell states associated with response to checkpoint immunotherapy in melanoma","volume":"175","author":"Sade-Feldman","year":"2018","journal-title":"Cell"},{"key":"B60","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1172\/JCI45817","article-title":"Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors","volume":"122","author":"Salmon","year":"2012","journal-title":"J Clin Invest"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/nature25501","article-title":"TGF-beta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0315","article-title":"Myeloid cells orchestrate systemic immunosuppression, impairing the efficacy of immunotherapy against HPV-positive tumors","volume":"8","author":"Galliverti","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.4437","article-title":"Single-cell sequencing reveals dissociation-induced gene expression in tissue subpopulations","volume":"14","author":"van den Brink","year":"2017","journal-title":"Nat Methods"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-020-02048-6","article-title":"Systematic assessment of tissue dissociation and storage biases in single-cell and single-nucleus RNA-seq workflows","volume":"21","author":"Denisenko","year":"2020","journal-title":"Genome Biol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/s41591-020-0844-1","article-title":"A single-cell and single-nucleus RNA-seq toolbox for fresh and frozen human tumors","volume":"26","author":"Slyper","year":"2020","journal-title":"Nat Med"},{"key":"B66","doi-asserted-by":"publisher","first-page":"5692","DOI":"10.1038\/s41467-021-25960-2","article-title":"Confronting false discoveries in single-cell differential expression","volume":"12","author":"Squair","year":"2021","journal-title":"Nat Commun"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-021-00830-w","article-title":"Robust decomposition of cell type mixtures in spatial transcriptomics","volume":"40","author":"Cable","year":"2022","journal-title":"Nat Biotechnol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N Engl J Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00914","article-title":"First-line pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: final overall survival results of KEYNOTE-826","volume":"41","author":"Monk","year":"2023","journal-title":"J Clin Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01808-7","article-title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer: overall survival results from KEYNOTE-A18","volume":"404","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"key":"B71","unstructured":"FDA Approves Pembrolizumab With Chemoradiotherapy for FIGO 2014 Stage III\u2013IVA Cervical Cancer\n          \n          2024"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00479-5","article-title":"Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial","volume":"24","author":"Monk","year":"2023","journal-title":"Lancet Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112187","article-title":"Survival with cemiplimab in recurrent cervical cancer","volume":"386","author":"Tewari","year":"2022","journal-title":"N Engl J Med"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study","volume":"37","author":"Chung","year":"2019","journal-title":"J Clin Oncol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30104-3","article-title":"Nivolumab for previously treated unresectable metastatic anal cancer: a multicentre, single-arm, phase 2 study","volume":"18","author":"Morris","year":"2017","journal-title":"Lancet Oncol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00382-4","article-title":"Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the phase 2 KEYNOTE-158 study","volume":"7","author":"Marabelle","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100529","article-title":"A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202)","volume":"7","author":"Rao","year":"2022","journal-title":"ESMO Open"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00631-2","article-title":"Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303\/InterAACT-2): a global, phase 3 randomised controlled trial","volume":"405","author":"Rao","year":"2025","journal-title":"Lancet"},{"key":"B79","unstructured":"FDA Approves Retifanlimab-Dlwr With Carboplatin and Paclitaxel and as a Single Agent for Squamous Cell Carcinoma of the Anal Canal\n          \n          2025"},{"key":"B80","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1200\/JCO-25-00929","article-title":"NCI9673 (Part B): ETCTN randomized phase II study of nivolumab with or without ipilimumab in refractory, metastatic squamous cell carcinoma of the anal canal","volume":"44","author":"Morris","year":"2026","journal-title":"J Clin Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2022.01.029","article-title":"Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: results from the phase 2 KEYNOTE-158 study","volume":"166","author":"Shapira-Frommer","year":"2022","journal-title":"Gynecol Oncol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00739","article-title":"Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from CheckMate 358","volume":"37","author":"Naumann","year":"2019","journal-title":"J Clin Oncol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.3266","article-title":"Pembrolizumab plus platinum-based chemotherapy for patients with advanced penile cancer: the nonrandomized HERCULES clinical trial","volume":"11","author":"Cotait Maluf","year":"2025","journal-title":"JAMA Oncol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.04.021","article-title":"Retifanlimab in advanced penile squamous cell carcinoma: the phase 2 ORPHEUS study","volume":"8","author":"Garcia Del Muro","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02894","article-title":"Atezolizumab with or without radiotherapy for advanced squamous cell carcinoma of the penis (PERICLES): a phase II trial","volume":"41","author":"de Vries","year":"2023","journal-title":"J Clin Oncol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00239-1","article-title":"Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting HPV16 and HPV18 E6 and E7 proteins for cervical intraepithelial neoplasia 2\/3: a randomised, double-blind, placebo-controlled phase 2b trial","volume":"386","author":"Trimble","year":"2015","journal-title":"Lancet"},{"key":"B87","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1001\/jamaoncol.2018.4051","article-title":"Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable HPV16-related cancer: a phase 2 clinical trial","volume":"5","author":"Massarelli","year":"2019","journal-title":"JAMA Oncol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30486-1","article-title":"Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV16-positive or HPV18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial","volume":"21","author":"Youn","year":"2020","journal-title":"Lancet Oncol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000001235","article-title":"A randomized phase 2 study of axalimogene filolisbac, a Listeria monocytogenes-based immunotherapy, with or without cisplatin in recurrent cervical cancer","volume":"28","author":"Basu","year":"2018","journal-title":"Int J Gynecol Cancer"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.9093","article-title":"Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells","volume":"33","author":"Stevanovic","year":"2015","journal-title":"J Clin Oncol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02424","article-title":"T-cell receptor gene therapy for human papillomavirus-associated epithelial cancers: a first-in-human, phase I\/II study","volume":"37","author":"Doran","year":"2019","journal-title":"J Clin Oncol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-01225-1","article-title":"TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers","volume":"27","author":"Nagarsheth","year":"2021","journal-title":"Nat Med"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2026.1809354","article-title":"A phase 1 trial of HPV16 E7 T-cell receptor-engineered T cells in relapsed or refractory HPV16-positive cancers: the KITE-439 trial","volume":"16","author":"Kirtane","year":"2026","journal-title":"Front Oncol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2026.04.007","article-title":"Pembrolizumab plus olaparib in recurrent cervical cancer progressing after platinum-based chemotherapy: the GOTIC-025 phase II study","volume":"208","author":"Ogasawara","year":"2026","journal-title":"Gynecol Oncol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00954","article-title":"Clinical validation of human papillomavirus circulating tumor DNA for early detection of residual disease after chemoradiation in cervical cancer","volume":"42","author":"Han","year":"2024","journal-title":"J Clin Oncol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-2575","article-title":"Time dependency for human papillomavirus circulating tumor DNA detection after chemoradiation as a prognostic biomarker for localized anal cancer","volume":"31","author":"Morris","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0922","article-title":"Prognostic impact of residual HPV circulating tumor DNA detection after chemoradiotherapy for anal squamous cell carcinoma","volume":"24","author":"Cabel","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B98","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41698-024-00778-5","article-title":"Deep learning for predicting prognostic consensus molecular subtypes in cervical cancer from histology images","volume":"9","author":"Wang","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078378","article-title":"TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods","volume":"385","author":"Collins","year":"2024","journal-title":"BMJ"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-082505","article-title":"PROBAST+AI: an updated tool for assessing risk of bias and applicability of prediction models using regression or artificial intelligence methods","volume":"388","author":"Moons","year":"2025","journal-title":"BMJ"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1034-x","article-title":"Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension","volume":"26","author":"Liu","year":"2020","journal-title":"Nat Med"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1507","article-title":"The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition","volume":"22","author":"Hegde","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B103","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat Rev Drug Discov"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1937031\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:09:51Z","timestamp":1790082591000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1937031\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":103,"alternative-id":["10.3389\/fimmu.2026.1937031"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1937031","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"article-number":"1937031"}}